Hostname: page-component-586b7cd67f-l7hp2 Total loading time: 0 Render date: 2024-11-24T17:26:10.896Z Has data issue: false hasContentIssue false
  • English
  • Français

Long acting antipsychotics treatment of schizophrenia: A 24-month prospective study on patient's attitude towards treatment

Published online by Cambridge University Press:  23 March 2020

E. Calderani ,
F. Pietrini ,
I. Burian ,
F. Chiarello ,
D. Dahlke ,
S. Gemignani ,
P. Marino ,
G.A. Talamba ,
L. Poli  and
A. Santangelo
...Show all authors
E. Calderani
Affiliation:
University of Florence, Neuro. Far. Ba, University of Florence, Florence, Italy
F. Pietrini
Affiliation:
University of Florence, Neuro. Far. Ba, University of Florence, Florence, Italy
I. Burian
Affiliation:
University of Florence, Neuro. Far. Ba, University of Florence, Florence, Italy
F. Chiarello
Affiliation:
University of Florence, Neuro. Far. Ba, University of Florence, Florence, Italy
D. Dahlke
Affiliation:
University of Florence, Neuro. Far. Ba, University of Florence, Florence, Italy
S. Gemignani
Affiliation:
University of Florence, Neuro. Far. Ba, University of Florence, Florence, Italy
P. Marino
Affiliation:
University of Florence, Neuro. Far. Ba, University of Florence, Florence, Italy
G.A. Talamba
Affiliation:
University of Florence, Neuro. Far. Ba, University of Florence, Florence, Italy
L. Poli
Affiliation:
University of Florence, Neuro. Far. Ba, University of Florence, Florence, Italy
A. Santangelo
Affiliation:
University of Florence, Neuro. Far. Ba, University of Florence, Florence, Italy
V. Ricca
Affiliation:
University of Florence, Neuro. Far. Ba, University of Florence, Florence, Italy
A. Ballerini
Affiliation:
University of Florence, Neuro. Far. Ba, University of Florence, Florence, Italy

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

Long-acting injectable (LAI) second-generation antipsychotics (SGAs) are considered an alternative to oral antipsychotics for schizophrenic patients with low adherence to therapy. However, it is still a matter of debate whether LAI-SGAs are able to significantly improve patient's attitudes towards treatment (ATT) [1].

Objective

To investigate the impact of LAI on ATT over 24 months.

Methods

Nineteen schizophrenic patients were switched from either oral olanzapine (11) or paliperidone (8) to the corresponding LAI. Patients were assessed at baseline (T0), after 6 (T1), 12 (T2) and 24 months (T3). Drug Attitude Inventory-10 (DAI-10) [2] was used to assess ATT. Young Mania Rating Scale (YMRS), Montgomery-Asberg Depression Rating Scale (MADRS), Positive and Negative Syndrome Scale (PANSS), and Short Form Health Survey (SF-36) were used for psychopathology evaluations.

Results

Eleven patients reached T3. Eight patients were excluded (4 olanzapine, 4 paliperidone): 4 required a significant change in concomitant treatment, 4 a change of antipsychotic (metabolic comorbidity). No changes in psychopathology occurred between T2 and T3, some scales improved from baseline to T2. DAI-10 mean scores were improved after 12 months, thus not significantly, and were further improved at 24 months (P = .008 vs baseline).

Conclusions

ATT keeps improving after one year of LAI treatment, unrelated to clinical response.

Disclosure of interest

The authors have not supplied their declaration of competing interest.

Type
e-Poster walk: Schizophrenia and other psychotic disorders–part 1
Information
European Psychiatry , Volume 41 , Issue S1: Abstract of the 25th European Congress of Psychiatry , April 2017 , pp. S188
Copyright
Copyright © European Psychiatric Association 2017

References

Kaplan, G., Casoy, J., Zummo, J.Impact of long-acting injectable antipsychotics on medication adherence and clinical, functional, and economic outcomes of schizophrenia. Patient Prefer Adherence 2013; 7: 1171–118010.2147/PPA.S53795CrossRefGoogle ScholarPubMed
Nielsen, R.E., Lindström, E., Nielsen, J., Levander, S.DAI-10 is as good as DAI-30 in schizophrenia. Eur Neuropsychopharmacol 22102012 74775010.1016/j.euroneuro.2012.02.008CrossRefGoogle Scholar
Submit a response

Comments

No Comments have been published for this article.